Reltecimod

Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs) [1][2].

Product Specifications

CAS Number

[1447799-33-8]

Product Name Alternative

AB-103

UNSPSC

12352209

Target

Bacterial; CD28

Type

Peptides

Related Pathways

Anti-infection; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/reltecimod.html

Purity

99.88

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](CC(O)=O)C(N[C@H](C)C(O)=O)=O)=O)NC([C@H](C)NC([C@H](C(C)C)NC([C@H](CC(C)C)NC([C@H](CCSC)NC([C@H]2N(CCC2)C([C@H](CO)NC([C@H](N)C)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C46H72N10O15S

Molecular Weight

1037.19

References & Citations

[1]Shirvan, A., et al. Reltecimod. T-cell-specific surface glycoprotein CD28 (TP44) antagonist, CD28 homodimer interface mimetic peptide, Treatment of necrotizing soft-tissue infection. Drugs Fut 2018, 43 (4) : 243|[2]Edgar, R., Tarrio, M.L., Maislin, G. et al. Treatment with One Dose of Reltecimod is Superior to Two Doses in Mouse Models of Lethal Infection. Int J Pept Res Ther 26, 1669–1683 (2020) .